600521 華海藥業
按盤價 
18.980 +0.550 (+2.984%) | 2025/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 2,368,564 | -5.21% | 9,547,425 | 8,308,720 | 8,265,745 | 6,643,573 | |
| 減：營業總成本 | 2,002,447 | -4.60% | 7,978,739 | 7,096,900 | 6,635,694 | 6,300,680 | |
| 其中:營業成本 | 834,236 | -17.08% | 3,636,604 | 3,288,338 | 3,110,936 | 2,657,134 | |
| 財務費用 | 47,473 | 13.81% | 95,480 | 137,247 | (10,833) | 188,184 | |
| 資產減值損失 | (19,484) | -844.03% | (122,874) | (117,176) | (70,604) | (13,928) | |
| 公允價值變動收益 | 13,254 | -122.54% | (69,493) | (100,248) | 5,201 | 299,808 | |
| 投資收益 | (8,002) | 11.56% | (28,720) | (62,652) | (75,205) | 147,151 | |
| 其中：對聯營企業和合營企業的投資收益 | (8,036) | 6.41% | (28,660) | (27,700) | (42,191) | (41,774) | |
| 營業利潤 | 376,769 | 0.57% | 1,470,789 | 1,124,540 | 1,547,171 | 868,399 | |
| 利潤總額 | 375,012 | 0.85% | 1,463,608 | 1,100,321 | 1,508,900 | 786,928 | |
| 減：所得稅費用 | 78,973 | -19.33% | 356,145 | 283,072 | 332,890 | 306,284 | |
| 淨利潤 | 296,040 | 8.07% | 1,107,463 | 817,249 | 1,176,009 | 480,644 | |
| 減：非控股權益 | (1,364) | -143.99% | (11,518) | (13,217) | 8,251 | (6,891) | |
| 股東淨利潤 | 297,404 | 9.81% | 1,118,981 | 830,466 | 1,167,759 | 487,535 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.210 | 10.53% | 0.770 | 0.570 | 0.810 | 0.340 | |
| 每股派息 (元) * | -- | -- | 0.250 | 0.200 | 0.240 | 0.100 | |
| 每股淨資產 (元) * | 6.326 | 16.08% | 5.903 | 5.286 | 4.925 | -- | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 06/06/2025 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
